JamesDirkIglehartMD
General Surgery • Boston, MABreast, Surgical Oncology (Other than Breast)
Anne E. Dyson Professor in Women's Cancers, Dana-Farber Cancer Institute
Are you Dr. Iglehart?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 58 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
Brigham And Womens Hospital
Boston, MA 02115Phone+1 617-732-6437
Summary
- Dr. James Iglehart, MD is a general surgeon in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Dana-Farber Cancer Institute and Salem Hospital.
Education & Training
Duke University HospitalFellowship, Thoracic Surgery, 1977 - 1984- Duke University HospitalResidency, Surgery, 1975 - 1977
Harvard Medical SchoolClass of 1975
Certifications & Licensure
MA State Medical License 1999 - 2018
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2003-2014
- Boston Magazine Castle Connolly, 2008-2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Publications & Presentations
PubMed
- 402 citationsTelomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging AgentsNicolai Juul Birkbak, Zhigang C. Wang, Ji Young Kim, Aron Charles Eklund, Qiyuan Li
Cancer Discovery. 2012-04-01 - 323 citationsCDK7-Dependent Transcriptional Addiction in Triple-Negative Breast CancerYubao Wang, Tinghu Zhang, Nicholas Kwiatkowski, Brian J. Abraham, Tong Ihn Lee
Cell. 2015-09-24 - 125 citationsProfiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment OutcomeZhigang C. Wang, Nicolai Juul Birkbak, Aedín C. Culhane, Ronny Drapkin, Aquila Fatima
Clinical Cancer Research. 2012-10-15
Grant Support
- Communications, Planning And Administration CoreNational Cancer Institute2008–2009
- Avon SupplementNational Cancer Institute2008–2009
- Developmental Research ProgramNational Cancer Institute2005–2009
- Career Development ProgramNational Cancer Institute2005–2009
- Dana-Farber/Harvard Spore In Breast CancerNational Cancer Institute2000–2009
- Avon-Nci PFP PROGRAM: Predicting Treatment Response In ER Positive Breat CancerNational Cancer Institute2008
- Avon NCI Progress For Patients SupplementNational Cancer Institute2008
- Advanced Training In Surgical OncologyNational Cancer Institute2001–2008
- C-6: Communications, Planning, And AdministrationNational Cancer Institute2005–2007
- Developmental ProjectsNational Cancer Institute2000–2002
- Career Development AwardsNational Cancer Institute2000–2002
- Developmental Research ProgramNational Cancer Institute1997–2002
- Core--Breast Cancer Tissue And Animal Testing ResourceNational Cancer Institute1997–2002
- Career Development ProgramNational Cancer Institute1997–2002
- Spore In Breast CancerNational Cancer Institute1995–1998
- Planning A Program Of Research In Early Breast CancerNational Cancer Institute1994–1997
- Planning A Program Of Research In Early Breast CancerNational Cancer Institute1994
- P53 In Breast CancerNational Cancer Institute1994
- P53 In Human Breast CancerNational Cancer Institute1992–1993
- Expression Of Oncogenes In Human TumorsNational Cancer Institute1991
- Expression Of Oncongenes In Human TumorsNational Cancer Institute1988
- Expression Of RAS Oncogenes In Human TumorsNational Cancer Institute1986–1987
- Immunotherapy Of Murine Solid TumorsNational Cancer Institute1985
Professional Memberships
- Member
